Safety issues in methadone maintenance therapy, part 2: Clinical and pharmacological apects;Sicherheitsaspekte in der methadonsubstitution - Teil 2: Klinisch-pharmakologische aspekte

Suchtmedizin in Forschung und Praxis

Volumn 10, Issue 2, 2008, Pages 119-144

  Soyka, Michael ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b PF 612 ^*  (Switzerland)

Author keywords

Methadone; Mortality; Safety; Therapy

Indexed keywords

ABACAVIR; AMITRIPTYLINE; AMPRENAVIR; CARBAMAZEPINE; DEXAMETHASONE; DIAZEPAM; DISULFIRAM; EFAVIRENZ; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; HYPERICUM PERFORATUM EXTRACT; ISONIAZID; KETOCONAZOLE; LOPINAVIR; METHADONE; MIDAZOLAM; MOCLOBEMIDE; NELFINAVIR; NEVIRAPINE; PAROXETINE; PHENYTOIN; QUETIAPINE; RIFABUTIN; RISPERIDONE; RITONAVIR; SAQUINAVIR; UNINDEXED DRUG; VORICONAZOLE;

CARDIOTOXICITY; COGNITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; GRAPE JUICE; HUMAN; HYPERICUM PERFORATUM; HYPOKALEMIA; MAINTENANCE THERAPY; MORTALITY; QT PROLONGATION; REVIEW; TORSADE DES POINTES;

EID: 47549102988     PISSN: 14375567     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (157)

1. Almehmi A, Malas AM, Yousufuddin M, Rosencrance JG (2004): Methadon-induced torsade de pointes in a patient with normal baseline QT interval. WV Med J 100: 147-148
2. Altice FL, Friedland GH, Cooney EL et al. (1999): Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 13: 957-962
3. Appel PW, Gordon NB (1976): Digit-symbol performance in methadone-treated ex-heroin addicts. Am J Psychiatry 133: 337-1340
4. Backmund M, Henkel C, Jordan F, Habsch J, Meyer K, Kääb S (2005): Das QT-Intervall während der Substitutionsbehandlung Heroinabhängiger. Suchtmed 7: 161-164
5. Baden MM (1978): Evaluation of deaths in methadone users. Leg Me Annu 1978: 127-131
6. Barret DH, Luk AJ, Parrish RG, Jones TS (1996): An investigation of medical examiner cases in which methadone was detected, Harris County, Texas, 1987-1992. J Forensic Sci 41 (3): 442-448
7. Bart PA, Rizzardi PG, Gallant S et al. (2001): Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther Drug Monit 23: 553-555
8. Batki SL, Manfredi LB, Jacob PIII et al. (1993): Fluoxetine for cocaina dependance in methadone maintenance: quantitative plasma and urine cocaine benzoylecgonine concentrations. J Clin Psychopharmacol 13: 243-250
9. Beauverie P, Taburet AM, Dessalles MC et al. (1998): Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors. AIDS 12: 2510-2511
10. Begré S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Powell Golay K, Kosel M, Baumann P, Eap CB (2002): Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 22: 211-215
11. Bell J, Zador D (2000): A risk-benefit analysis of methadone maintance treatment. Drug-Saf 22 (3): 179-190
12. Benmebarek M, Devaud C, Gex-Fabry M, Powell Golay K, Brogli C, Baumann P, Gravier B, Eap CB (2004): Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. Clinical Pharmacology and Therapeutics 76 (1): 55-63
13. Bertschy G, Eap CB, Powell K et al. (1996): Fluoxetine addition to methadone in addicts: pharmacokinetic aspects. Ther Drug Monit 18: 570-572
14. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM et al. (1998): Single-nucleotide polymorphism in the human mu opioid receptor gene alters b-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95: 9608-9613
15. Borg L, Kreek MJ (1995): Clinical problems associated with interactions between methadone pharmacotherapy and medications used in the treatment of HIV-1-positive and AIDS patients. Curr Opin Psychiatry 8: 199-202
16. Bouer R, Barthe L, Philibert C et al. (1999): The roles of P-glycoprotein and intracellular metabolism in the intestinal sac. Fundam Clin Pharmacol 13: 494-500
17. Brown FM, Griffiths PS (2000): P450Guide: Comprehensive Enzymatic Drug Metabolism Reference. 2nd Ed. Montgomery, AL
18. Callaghan R, Riordan JR (1993): Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem 268: 16059-16064
19. Cantilena L, McCrea J, Blazer D, Winchell G, Carides A, Royce C et al. (1999): Lack of a pharmacokinetic interaction between indinavir and methadone (abstract PI-174). Clin Pharmacol Ther 65: 135
20. Caplehorn JR, Dalton MS, Cluff MC, Petrenas AM (1994): Retention in methadone maintenance and heroin addicts' risk of death. Addiction 89: 203-209
21. Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K (2008): A community-based evaluation of sudden death with therapeutic levels of methadone. Am J Med 121 (1): 66-71
22. Clark N, Lintzeris N, Gijsbers A, Whelan G, Dunlop A, Ritter A et al. (2002): LAAM maintenance vs methadone maintenance for heroin dependence [Cochrane review]. Cochrane Database Syst Rev 2002, Issue 2
23. Clarke SM, Mulcahy FM, Tjia J et al. (2001a): Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 33: 1595-1597
24. Clarke SM, Mulcahy FM, Tjia J et al. (2001b): The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 51: 213-217
25. Cobb MN, Desai J, Brown LS Jr et al. (1998):The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther 63: 655-662
26. Codd EE, Shank RP, Schupsky JJ, Raffa RB (1995): Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: Structural determinants and role in antinociception. J Pharmacol Exp Ther 274: 1263-1270
27. Cooncool B, Smith H, Stimmel B (1979): Mortality rates of persons entering methadone maintenance: a seven-year study. American Journal of Drug and Alcohol Abuse 6: 345-353
28. Cozza KL, Armstrong SC (2001): The Cytochrome P450 system. Drug interaction principles for medical practice. Washington DC, Am Psychiatric Press
29. Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hämmig R, Monnat M, Hüttemann H, Baumann P, Eap CB (2005): Methadone enantiomer plasma levels, CYP2B6, CYP2C19 and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78: 593-604
30. Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Hämmig R, Gothuey I, Monnat M, Eap CB (2006): ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80: 668-681
31. Curran HV, Kleckham J, Beam J, Strang J, Wanigarante S (2001): Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: a dose-response study. Psychopharmacology (Berl) 129: 329-338
32. Darke S, Sims J, McDonald S, Wickens W (2000b): Cognitive impairment among methadone maintenance patients. Addiction 95: 687-695
33. Davis PE, Liddiard H, McMillan TM (2002): Neuropsychological deficits and opiate abuse. Drug Alcohol Depend 67: 687-695
34. Davoli M, Peducci CA, Forestiere F, Doyle P, Rapiti E, Maccarelli M, Abenti DD (1993): Risk factors for overdose mortality: a case control study within a cohort of intravenous drug users. International Journal of Epidemiology, 22, 273-277
35. De Maat MMR, Ekhart GC, Huitema ADR, Koks CHW, Mulder JW, Neijnen JH (2003): Drug interactions between antiretroviral drugs and comdicatd agents. Clin Pharmakokinet 42: 223-282
36. Dittert S, Naber D, Soyka M (1999): Methadonsubstitution und Fahrtauglichkeit-Ergebnisse einer experimentellen Studie. Nervenarzt 70: 457-462
37. Dole VP, Nyswander ME (1965): A medical treatment for diacetylmorphine (heroin) addiction: A clinical trial with methadone hydrochloride. JAMA 193: 80-84
38. Eap CB, Bertschy G, Powell K, Baumann P (1997): Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol 17: 113-117
39. Eap CB, Broly F, Mino A et al. (2000): Cytochrome P4502D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 21: 229-234
40. Eap CB, Buclin T, Baumann P (2002): Interindividual variability of the clinical pharmacokinetics of opioid dependence. Clin Pharmacokinet 41: 1153-1193
41. Eap CB, Crettol S, Rougier JS et al. (2007): Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 81: 719-728
42. Eap CB, De'Geon JJ, Baumann P (1999): Pharmacokinetics in pharmacokinetics of methadone: clinical relevance. Heroin Addict Relat Clin Publ 1: 19-34
43. Eap CB, Felder C, Golay KP, Uehlinger C (2003): Increase of oral methadone dose in methadone injecting patients: a pilot study. J Addict Dis 22: 7-17
44. Eap CB, Finkbeiner T, Gastpar M et al. (1996): Replacement of (R)-methadone by a double dose of (R, S)-methadone in addicts: inter-individual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. Eur J Clin Pharmacol 50: 385-398
45. Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, Piguet V, Musset T, Gaspoz JM, Perrier A, Dayer P, Desmeules JA (2006): Drug-induced ling QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk actors. Arch Intern Med 26: 1280-1287
46. Eich-Höchli D, Oppliger R, Powell Goday K, Baumann P, Eap CB (2003): Methadone maintenance treatment and St. John's wort - a case report. Pharmacopsychiatry 36: 35-37
47. Elsner H (2005): Kammertachykardien ("Torsade de Pointes) und weitere Herzrhytmusstörungen unter Methadonsubstitiution: Risikominderung durch Medikamentenumstellung. Suchtmed 7: 257-263
48. Engström A, Adamsson CM, Allebeck P, Rydberg W (1991): Mortality in patients with substance abuse: a follow-up in Stockholm County, 1973-1984, International Journal of the Addictions 26: 91-106
49. Fanoe S, Hvidt C, Ege P, Jensen GB (2007):Sincope and QT prolongation among patients treated with metadone for heroin dependance in the city of Copenhagen. Heart 93: 1051-1055
50. Ferrari A, Coccia CPR, Bertolini A, Sternieri E (2004): Methadone-metabolism, pharmacokinetics and interactions. Pharmacological Research 50, 551-559
51. Finelli P (1976): Phenytoin and methadone tolerance (letter). N Engl J Med 294: 227
52. Foster DJ, Somogyi AA, Bochner F (1999): Methadone N-demethylation in human livermicrosomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 47: 403-412
53. Foster DJR, Somogyi AA, Dyer KR et al. (2000): Steady-state pharmacokinetics of (R) and (S)-methadone maintenance patients. Br J Clin Pharmacol 50: 427-440
54. Foster DJR, Somogyi AA, White JM, Bochner F (2004): Population pharmacokinetics of (R), (S)-and rac-methaone on methadone maintenance patients. Br J Pharmacol 57: 742-755
55. Fraser HF, Isbell H (1962): Human pharmacology and addictiveness of certain dextroisomers of sythetic analgesice. Bull Narcotics 14: 25-35
56. Gardner R (1970): Deaths in United Kingdom opioid users, 1965-1968. Lancet 26, 650-653
57. Gearing FR, Schweitzer MD (1974): An epidemologic evaluation of long-term methadone maintenancetreatmentfor heroin addiction. American Journal of Epidemology 100, 101-112
58. Gerber JG, Rhodes RJ, Gal J (2004): Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6and 2C19. Chirality 16: 36-44
59. Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D et al. (2001): Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J AIDS 27: 153-160
60. Gil M, Sala M, Anguera I et al. (2003): QT prolongation and Torsade de Pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J cardiol 92: 995-997
61. Goldstein A, Herrara J (1995): Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug and Alcohol Dependence 40: 139-150
62. Gorman AL, Elliott KJ, Inturrisi CE (1997): The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 223: 1-4
63. Gourevitch MN, Friedland GH (2000): Interactions between methadone and medications used to treat HIV infection : a review. Mt Sinai J Med 67: 429-436
64. Grevert P, Msovr B, Goldstein A (1977): Failure of methadone and levomethadyl acetate (levo-alpha-acetylmethadol, LAAM) maintenance to affect memory. Arch Gen Psychiatry 34: 849-853
65. Grotz ER, Shiffman SM, Jarvik ME, Haber J, Dymond AM, Coger R et al. (1975): Physiological and psychological effects of methadone in man. Arch Gen Psychiatry 32: 237-242
66. Gruber SA, Tzilos GK, Silveri MM, Pollack M, Renshaw PF, Kaufman MJ, Yurgelun-Todd DA (2006): Methadone Maintenance Improves Cognitive Performance After Two Months of Treatment. Exp Clin Psychopharmacology 14: 157-164
67. Harding-Pink D (1991): Les décès associés àla methadone. J Toxicol Clin Exp 11: 31-49
68. Heelon MW, Meade LB (1999): Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy 19: 471-472
69. Heinemann A, Andresen H, Raschke P (2005): Methadonassoziierte Mortalität von Opiatkonsumenten in Hamburg 1990 bis 2001. Suchtmed 7(1): 27-32
70. th ICAAC, San Francisco, September 17-20, 2000
71. Hendrix CW, Wakeford J, Wire BT et al. (2004): Pharmacokinetics and Pharmacodynamics of Methadone Enantiomers After Coadministration with amprenavir in Opioid-Dependent Subjects. Pharmacotherapy 24: 1110-1121
72. Hsu A, Granneman GR, Cao G et al. (1998): Pharmacokinetic interactions between two immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 63: 453-464
73. Huang L, Wring SA, Woolley JL et al. (2001): Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 29: 754-760
74. Ikeda K et al. (2005): How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci 26: 311-317
75. Iribarne C, Berthou F, Baird S et al. (1996): Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 9: 365-373
76. lribarne C, Picart D, Dreano Y et al. (1998): In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundam Clin Pharmacol 12: 194-199
77. Justo D (2006): Methadone-Induced Long QT Syndrome vs Methadone-Induced Torsades de Pointes. Arch Intern Med 166: 2288
78. Karch SB, Stephens BG (2000): Toxicology and pathology of deaths related to methadone: retrospective review. West J Med 172: 11-14
79. Katchman AN, McGroary KA, Kilborn MJ, Kornick CA, Manfredi PL, Woosley RL, Ebert SN (2002): Influence of opioid agonists on cardiac human ether-a-go-go-related gene K (+) currents. J Pharmacol Exp Ther 303: 688-694
80. Kharasch ED, Hoffer C, Whittington D, Sfeffels P (2004): Role of hepatic and intestinal P450 3A and 2B6 in the metabolism, disposition, and miotic ffects of methadone. Clin Pharmacol Ther 76: 250-259
81. Kornick CA, Kilborn MJ, Santiago-Palma J et al. (2003): QTc interval prolongation associated with intravenous methadone. Pain 105: 499-506
82. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS (2003): Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 23: 802-805
83. Krantz MJ, Rowan SB, Schmittner J, Bucher Bartelson B (2007): Physican awareness of the cardiac effects of methadone: results of a national survey. J Addict Dis 26: 79-85
84. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS (2002): Torsade de Pointes Associated with Very-High-Dose Methadone. Ann Intern Med 137: 501-504
85. Krantz, MJ, Mehler PS (2006): QTc prolongation: methadone's efficacy-safety paradox. Lancet 368, 556-557
86. Kreek MJ (1976): Metabolic interactions between opiates and alcohol. Ann N Y Acad Sci 281: 36-49
87. Kreek MJ, Hachey DL, Klein PD et al. (1982): Stereoselektive disposition of methadone in man. Life Sci 24: 925-932
88. Kreek MJ, Schecter AJ, Gutjahr CL et al. (1980): Methadone use in patients with chronic renal disease. Drug Alcohol Depend 5: 197-205
89. Leavitt SB, Shinderm,an M, Maxwell S, Eap CB, Paris P (2000): When "nough" is not enough: new perspectives on optimal methadone dose. Mt Sinai J Med 67: 404-411
90. Lee TM, Pau CW (2002): Impulse control differences between abstinent heroin users and matched controls. Brain Inj 16: 885-889
91. Lehder DM, Arria A, Artigiani EE, Wish ED (2002): Alcohol and drug-related overdose deaths in Maryland: 1997-2001. College Park, MD; Center for Substance Abuse Research (CESAR), University of Maryland
92. Lenne MG, Dietze P, Rumbold GR, Redman JR, Triggs TJ (2003): The effects of the opioid pharmacotherapies methadone, LAAM and buprenorphine, alone and in combination with alcohol, on stimulated driving. Drug Alcohol Depend 72: 271-278
93. Liu P, Foster G, Labadie R, Somoza E, Sharma A (2007): Pharmacokinetic interaction between voriconacole and methadone at steady state in patients on methadone therapy. Antimicrob Agents Chemother 51: 110-118
94. Liu S-J, Wang RIH (1976): Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome. Am J Psychiatry 141: 1287-1288
95. Lötsch J, Geisslinger G (2005): Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 11: 82-89
96. Lyvers M, Yakimoff M (2003): Neuropsychological corrlates of opioid dependence and withdrawal in opioid-dependent human volunteers. Addict Behav 28: 605-611
97. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A (2005): QTC interval prolongation in patients on long-term metadone maintenance therapy. Eur Addict Res 11: 44-49
98. Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN (2005): Impact of methadone treatment on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacotherapy 25: 611-614
99. Marzolini C, Paus E, Buclin T, Kim RB (2004): Polymorphisms in human MDR1 (P-glycoprotein) : recent advances and clinical relevance. Cin Pharmacol Ther 75: 13-33
100. Marzolini C, Troillet N, Telenti A et al. (2000): Efavirenz decreases methadone blood concentrations. AIDS 14: 1291-1292
101. Maxwell S, Shinderman M, Minder A, et al. (2002): Correlation between Hepatitis C serostatus and methadone dose requirement in 1163 methadone-maintained patients. Heroin Add & Rel Clin Prob 4: 5-10
102. McCance-Katz EF, Rainey PM, Friedland G, Jatlow P (2003): The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. CID 37: 476-482
103. Mintzer MZ (2007): Effects of Opiod Pharmacitherapy on Psychomotor and Cognitive Performance: a review of human laboratory Studies of Methadone and Buprenorphine. Heroin Addict Relat Clin Probl 9: 5-24
104. Mintzer MZ, Copersino ML, Sitzer ML (2005): Opioid abuse and cognitive performance. Drug Alcohol Depend 78: 225-230
105. Mintzer MZ, Stitzer ML (2002): Cognitive impairment in methadone maintenance patients. Drug Alcohol Depend 67: 41-51
106. Mitchell TB, Dyer KR, Newcombe D. Salter A, Somogyi AA, Bochner F, White JM (2004): Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (s)- vs. (R)-methadone exposure. Br J Clin Pharmacol 58: 609-617
107. Moody DE, Alburges ME, Parker RJ et al. (1997): The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetyl-methadol (LAAM), norlaam, and methadone. Drug Metab Dispos 25: 1347-1353
108. Moskowitz H, Robinson CD (1985): Methadone maintenance and tracking performance. In: Kaye S, Maier GW (eds): Alcohol, Drugs and traffic safety. Us Department of Transpotation, 995-1004
109. Nakamura K, Hachey DL, Kreek MJ et al. (1982): Quantitation of methadone enantiomers in humans using stable isotopelabeled (2H3)-and (2H8) methadone. J Pharm Sci 71: 40-43
110. Novick DM, Kreek MJ, Arns PA et al. (1985): Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients. Alcohol Clin Exp Res 9: 349-354
111. Novick DM, Kreek MJ, Fanizza AM et al. (1981): Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther 30: 353-362
112. Okruhlica L, Klempova D (2000): Hepatitis C infected patients and higher doses of methadone. Heroin Addict Relat Clin Probl 2: 57-58
113. Olsen GD, Wendel HA, Livermore JD et al. (1977): Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther 21: 147-157
114. Otero MJ, Fuertes A, Sanchez R et al. (1999): Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. AIDS 13: 1004-1005
115. Pau CWH, Lee TMC, Chan SF (2002): The impact of heroin on frontal executive functions. Arch Clin Neuropsychology 17: 663-670
116. Payte JT, Zweben JE (1998): Opioid maintenance therapies. In: Graham AW, Schultz TK (Eds.) Principles of Addiction Medicine. Chevy Chase, Maryland: American Society of Addiction Medicine
117. Pearson EC, Woosley RL (2005): QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 14: 747-753
118. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M (2007): Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction 102: 289-300
119. Penning R, Betz P, v.Meyer L, Soyka M (1992): Drogentodesfälle mit Methadon-beteiligung. Nervenheilkunde 4: 183-186
120. Penning R, v Meyer L, Sachs H, Zinka B (2005): Drogentodesfälle mit Methadonbeteiligung in den Jahren 2002 und 2003 - Daten des Instituts für Rechstmedizin. Suchtmed 7: 19-25
121. Pinzani V, Faucherre V, Peyriere H et al. (2000): Methadone withdrawal symptoms with nevirapine and efavirenz. Ann Pharmacother 34: 405-407
122. Plummer JL, Gourlay GK, Cherry DA et al. (1988): Estimation of methadone clearance: application in the management of cancer pain. Pain 33: 313-322
123. Prosser J, Cohen U, Steinfeld M, Eisenberg D, London ED, Galynker II (2006): Neuropsychological functioning in opaite-dependent subjects receiving and following methadone maintenance treatment. Drug Alcohol Depend 84: 240-247
124. Rostami-Hodjegan A, Wolff K, Hay AW et al. (1999): Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Pharmacol 48: 43-52
125. Rothenberg S, Schottnfeld S, Meyer Re, Krauss B, Gross K (1977): Performance difefrences between adicts and non-addicts. Psychopharmacology (Berl) 52: 299-306
126. Saxon AJ, Whittaker S, Hawker CS (1989): Valproic acid, unlike other anticonvulsants, has no effect on methadone metabolism: Two cases. J Clin Psychiatry 50: 228-229
127. Schindler SD, Ortner R, Peternell A, Eder H, Opgenoorth E, Fischer G (2004): Maintenance therapy with synthetic opioids and driving aptitude. Eur Addict Res 10: 80-87
128. Scott CC, Robbins EB, Chen KK (1948): Pharmacological comparison of the optical isomers of methdone. J Pharmacol Exp Therapeutics 20: 445-449
129. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco
130. Shelton Mj, Cloen D, DiFrancseso R et al. (2004): The Effects of Oncedaily Saquinavir/Minidose Ritonavir on the Pharmacokinetics of Methadone.J Clin Pharmacol 44: 293-304
131. Sims SA, Snow LA, Porucznik CA (2007): Surveillance of methadone-related adverse drug events using public helth data sources. J Biomedical Informatics 40: 382-389
132. Smith PF, Kearney BP, Liaw S et al. (2004): Effect of Tenofovir Disoproxil Fumarate on the Pharmacokinetics and Pharmacodynamics of total, R-, and S-Methadone. Pharmacotherapy 24: 970-977
133. Somogyi AA, Barratt DT, Coller JK (2007): Pharmacogenetics of Opiods. Clin Pharmacol Ther 81: 429-444
134. Sorg MH, Greenwald M (2002): Maine Drug-Related Mortality Patterns: 1997-2002. State of Maine: December 27, 2002
135. Soyka M, Apelt SM, Lieb M, Wittchen HU (2006): One year Mortality Rates of Patients Receiving Methadone and Buprenorphine Maintenance Therapy: A Nationally Representive Cohort Study in 2694 Patients. J Clin Psychopharmacol 26: 657-660
136. Soyka M, Hock B, Kagerer S, Lehnert R, Limmer C, Kuefner H (2005): Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients. J Clin Psychopharmacol 25: 1-4
137. Soyka M, Horak M, DittertS, Kagerer S (2001): Less driving impairment on buprenorphine than methadone in drug dependent patients. J Neuropsychiatry Clin Neurosci (letter) 13: 527-528.
138. Spaulding TC, Minium L, Kotake AN et al. (1974): The effect of diazepam on the metabolism of methadone by the liver of methadone-dependent rats. Drug Metab Dispos 2: 458-463.
139. Specka M, Finkbeiner T.lodemann E, leifert K, Kluwig J, Gastpar M (2000): Cognitive-motor performance of methadone-maintained patients. Eur Addict Res 6: 8-19
140. Sporer, KA (1999): Acute heroin overdose. Ann Intern Med 130: 584-590
141. Stimmel B, Lipski J, Swartz M, Donoso E: Electrocardiographic changes in heroins, methadone and multiple drug abuse: a postulated mechanism of sudden death in narcotic addicts. Proc Natl Conf Methadone Treat 1: 706-710
142. Taburet AM, Singlas E (1996): Drug interactions with antiviral drugs. Clin Pharmacokinet 30: 385-401
143. Ther L, Lindner E, Vogel C (1963): Zur pharmakodynamischen Wirkung der optischen Isomeren des Methadons. Deutsche Apothekerzeitung 17: 514-529
144. Tong TG, Pond SM, Kreek MJ et al. (1981): Phenytoin-induced methadone withdrawal. Ann Intern Med 94: 349-351
145. Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED (2007): Enantiomeric Metabolic Interactions and stereoselective Human Methadone Metabolism. J Pharmacol Exp Ther 321: 389-399
146. Trapnell CB, Klecker RW, Jamis-Dow C et al. (1998): Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproicacid. Antimicrob Agents Chemother 42: 1592-1596
147. Uehlinger C, Crettol S, Chassot P, Brocard M, Koeb L, Brawand-Amey M, Eap CB (2007): Increased (R)-Methadone Plasma Concentrations by Quetiapine in Cytochrome P450s and ABCB1 Genotyped Patients. Journal of Clinical Psychopharmacology 27 (3): 273-278
148. Verdejo A, Toribo I, Orozco C, Puente KL, Perez-Garcia M (2005): Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers. Drug Alcohol depend 78: 283-288
149. Violand C, Piguet V (2004): Methadon und dosisabhängiges Risiko von "Torsadede pointes" (Kammertachykardien) und QT-Verlängerung. Schweizerische Aerztezeitung 85: 95-96
150. Wang J-S, DeVane L (2003): Involvement of CYP3A4, CYP2C8, and CYP2DE6 in the Metabolism of (R)-and (S)-Methadone in vitro. Drug Metabol Disposition 31: 742-747
151. White J, Irvine R (1999): Mechanismsof fatal opioid overdose. Addiction 95: 961-972
152. Wittchen HU, Apelt S, Soyka M, Gastpar M, Backmund M, Gölz J, Kraus MR, Tretter F, Schäfer M, Siegert J, Scherbaum N, Rehm J, Bühringer G (2008): Feasibility and outcome of subtitution treatment of heroin-dependent patients in specialized subtitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: A naturalistic study in 2694 patients Alcohol Drug Depend 95: 245-257
153. Wolff K, Hay A, Raistrick D (1991): High-dose-methadone and the nead for drug measurements in plasma. Clin Chem 37: 1651-1664
154. Wolff K, Rostami-Hodjegan A, Hay AW et al. (2000): Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction 95: 1711-1783
155. Wolff K, Rostami-Hodjegan A, Shires S et al. (1997): The pharmacokinetics of methadone in healthy subjects and opiate users. Br Clin Pharmacol 44: 325-334
156. Wu C, Henry JA (1994): Interaction between ethanol and opioids in a protozoan assay. Hum Exp Toxicol 13: 145-148
157. Wu C, Otton SV, Sproule Ba, Busto U, Inaba T, Kalow W, Sellers EM (1993)Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Pharmacol 35: 30-34